Present and Future of Personalised Medicine for Endocrine Cancers
Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (140 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544866104498 |
---|---|
ctrlnum |
(CKB)5720000000008378 (oapen)https://directory.doabooks.org/handle/20.500.12854/84513 (EXLCZ)995720000000008378 |
collection |
bib_alma |
record_format |
marc |
spelling |
Ronchi, Cristina L. edt Present and Future of Personalised Medicine for Endocrine Cancers Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (140 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials. English Medicine bicssc papillary thyroid cancer SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing's disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters 3-0365-4330-9 3-0365-4329-5 Altieri, Barbara edt Ronchi, Cristina L. oth Altieri, Barbara oth |
language |
English |
format |
eBook |
author2 |
Altieri, Barbara Ronchi, Cristina L. Altieri, Barbara |
author_facet |
Altieri, Barbara Ronchi, Cristina L. Altieri, Barbara |
author2_variant |
c l r cl clr b a ba |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Present and Future of Personalised Medicine for Endocrine Cancers |
spellingShingle |
Present and Future of Personalised Medicine for Endocrine Cancers |
title_full |
Present and Future of Personalised Medicine for Endocrine Cancers |
title_fullStr |
Present and Future of Personalised Medicine for Endocrine Cancers |
title_full_unstemmed |
Present and Future of Personalised Medicine for Endocrine Cancers |
title_auth |
Present and Future of Personalised Medicine for Endocrine Cancers |
title_new |
Present and Future of Personalised Medicine for Endocrine Cancers |
title_sort |
present and future of personalised medicine for endocrine cancers |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (140 p.) |
isbn |
3-0365-4330-9 3-0365-4329-5 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT ronchicristinal presentandfutureofpersonalisedmedicineforendocrinecancers AT altieribarbara presentandfutureofpersonalisedmedicineforendocrinecancers |
status_str |
n |
ids_txt_mv |
(CKB)5720000000008378 (oapen)https://directory.doabooks.org/handle/20.500.12854/84513 (EXLCZ)995720000000008378 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Present and Future of Personalised Medicine for Endocrine Cancers |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548743197786112 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04194nam-a2200925z--4500</leader><controlfield tag="001">993544866104498</controlfield><controlfield tag="005">20231214133138.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202206s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5720000000008378</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/84513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995720000000008378</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ronchi, Cristina L.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Present and Future of Personalised Medicine for Endocrine Cancers</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (140 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">papillary thyroid cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SUV PET/CT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BRAF V600E</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors (ICIs)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ipilimumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nivolumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prolactinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cushing's disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aggressive pituitary tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aggressive PitNET</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aggressive pituitary adenoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pituitary carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adrenocortical cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adrenal adenomas</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adrenal tumors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">p53</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">p27</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ki-67</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reticulin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mitotane</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adjuvant treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recurrence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recurrence free survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">timing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intratumoral heterogeneity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thyroid tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BRAF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RET/PTC rearrangements</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RAS mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adrenal cortex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">osteopontin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hyaluronan synthase 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multikinase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sorafenib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lenvatinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">differentiated thyroid cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radioiodine resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive marker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">response to treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">information needs and preferences</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">focus group interview</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neuroendocrine tumours</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phaeochromocytoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">paraganglioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular clusters</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4330-9</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4329-5</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Altieri, Barbara</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ronchi, Cristina L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Altieri, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:44:02 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-02 22:45:44 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337782350004498&Force_direct=true</subfield><subfield code="Z">5337782350004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337782350004498</subfield></datafield></record></collection> |